National medicines strategy group recommends Sativex after first robust assessment1
- Following a health technology appraisal, Sativex has been recommended for the treatment of MS spasticity by the All Wales Medicines Strategy Group (AWMSG)(1)
- This is the first time Sativex has been comprehensively evaluated by a UK National HTA body
The AWMSG (www.awmsg.org) work in an advisory capacity to ensure equity of access to the most clinically appropriate and cost-effective medicines for the people of Wales. They bring together clinical experts, pharmacists, health economists, industry representatives and patient advocates to form a consensus on the use of medicines within primary and secondary care.
"This is great news for people with MS who have troublesome spasticity. Sometimes it is impossible to get adequate control with oral drugs such as baclofen, gabapentin† and tizanidine without causing intolerable side effects. Being able to prescribe THC:CBD spray (Sativex) gives us another option before escalating therapy to invasive treatments such as intrathecal baclofen. Better for the patients and clinically and cost-effective for the NHS!"
Val Stevenson, Consultant Neurologist, National Hospital for Neurology and Neurosurgery
†Gabapentin is not licensed for MS-associated spasticity.
- AWMSG, 2014. Sativex Preliminary Appraisal Recommendation. Available from:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/644 (last accessed February 2015)